Press Releases April 16, 2026 06:05 AM

MoneyHero Group to Announce Fourth Quarter and Full Year 2025 Results

MoneyHero to announce Q4 and full year 2025 financial results with a conference call scheduled on April 30, 2026

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
MNY

MoneyHero Limited, a tech- and AI-powered personal finance platform with operations in Greater Southeast Asia, will release its fourth quarter and full year 2025 results on April 30, 2026, and host a conference call to discuss the results. The company provides finance aggregation and digital insurance brokerage services and operates several well-known B2C and B2B brands in Asia.

MoneyHero Group to Announce Fourth Quarter and Full Year 2025 Results
MNY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MoneyHero serves Singapore, Hong Kong, Taiwan, and the Philippines with a focus on personal finance comparison and digital insurance brokerage.
  • The company boasts over 260 commercial partnerships and around 5.1 million monthly unique users as of September 2025.
  • Notable backers include Peter Thiel and Richard Li, indicating strong industry support and credibility.

SINGAPORE, April 16, 2026 (GLOBE NEWSWIRE) -- MoneyHero Limited (Nasdaq: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced that it will release its fourth quarter and full year 2025 results on Thursday, April 30, 2026 before market opens and will hold a related conference call to discuss the results at 8:00 a.m. EDT (or 8:00 p.m. Hong Kong/Singapore time) on the same day.

Investors and other interested parties may listen to the call by clicking on the registration link for the webcast or audio conference at:

Webcast: https://edge.media-server.com/mmc/p/ydx9uomn
Conference call: https://register-conf.media-server.com/register/BIaabf02b3f3514871ad56ad5092fa9ac3

The webcast replay will be available on the Investor Relations website for 12 months following the event.

About MoneyHero Group
MoneyHero Limited (NASDAQ: MNY) is a tech- and AI-powered personal finance aggregation and comparison platform that provides consumers with actionable insights to discover, compare, and choose the best financial products with confidence — bringing data intelligence and seamless digital access across insurance and banking solutions. The Company operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The Company also retains an equity stake in Malaysian fintech company, Jirnexu Pte. Ltd., parent company of Jirnexu Sdn. Bhd., the operator of RinggitPlus, Malaysia’s largest operating B2C platform. MoneyHero had over 260 commercial partner relationships as at September 30, 2025, and had approximately 5.1 million Monthly Unique Users across its platform for the three months ended September 30, 2025. The Company’s backers include Peter Thiel—co-founder of PayPal, Palantir Technologies, and the Founders Fund—and Hong Kong businessman, Richard Li, the founder and chairman of Pacific Century Group. To learn more about MoneyHero and how the innovative fintech company is driving APAC’s digital economy, please visit www.MoneyHeroGroup.com

For inquiries, please contact:

Investor Relations:
MoneyHero IR Team
[email protected]

Media Relations:
MoneyHero Corporate Communications Team
[email protected]


Risks

  • Financial results could be affected by market competition in the fintech and digital insurance sectors impacting revenue growth.
  • Operations across multiple countries may expose the company to geopolitical and regulatory risks in the Asia-Pacific region.
  • User engagement and partnership renewal rates may fluctuate, impacting platform traffic and monetization.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026